Stay current with MiRXES

Media Releases

Keep up to date with our latest news and activities as we continue to innovate and develop our science and technology, bringing novel products to market – from Singapore to the World.

10 August 2023

Mirxes announced today that its flagship product GASTROClearTM, a PCR-based in vitro diagnostic test for early detection of gastric (stomach) cancer, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). Globally, this marks the first time that 1) a blood miRNA test, 2) an in vitro diagnostic (IVD) test for early detection of gastric cancer, and 3) a molecular in vitro diagnostic test developed in Southeast Asia, has received a Breakthrough Device Designation from the U.S. FDA.

25 July 2023

Mirxes announced today the successful completion of its Series D funding round, securing a total of US$50 million. In addition to securing the Series D funding, Mirxes is pleased to announce that it has filed the listing application with The Stock Exchange of Hong Kong Limited (HKEX) under Chapter 18A of the Rules Governing the Listing of Securities on HKEX. 

29 November 2022

MiRXES signed a Memorandum of Understanding with PT ELION MEDIKA INDONESIA (PT ELION) to validate and commercialize MiRXES’s microRNA cancer blood tests for stomach and lung cancers in Indonesia, and establish CADENCE-ID, a joint project for the optimization and validation of a novel multi-cancer blood test, based on blood-borne circulating miRNA and DNA methylation biomarkers in the Indonesian population, for up to nine high incidence and high mortality cancers.

Media Coverage

Stay informed and keep abreast with our media news.

01 Jan 2024

Zao Bao – 1990 年代,从中国苏州到新加坡念中学,后上大学、读博士与创业,周砺寒碰上了生物医学领域在全球和新加坡发展浪潮的时代。叔叔胃癌病逝,让他领悟到病人、家属与医生的无能为力,思考生物医学“能不能不让同样的事再发生”。

22 Nov 2023

Straits Times – SINGAPORE – To watch a loved one wither away from terminal illness is terrifying and traumatic, what more to experience that as a teenager.


Our partnerships

17 Oct 2022

A new global landscape study found that only 10 to 30 per cent of healthtech innovations are clinically adopted in a widespread manner. The study – based on a survey of approximately 100 key opinion leaders across Australia, Israel, Singapore, UK and the US – also highlighted the need for a clearer pathway for new innovations in digital health, medical devices and therapeutics to be adopted clinically.

15 Sep 2021

ヒューマン・メタボローム・テクノロジーズ株式会社 代表取締役社長 橋爪 克仁 、 本社 山形県鶴岡市、以下「 HMT 」 と 、 MiRXES (ミレックサス Chief Executive Officer Zhou Lihan 、本社: シンガポール 、以下「 MiRXES 」 は、 マイクロ RNA 関連製品・サービスを日本において展開することに合意し、販売契約を締結しました 。


Welcome to our knowledge base of insights in the frontiers of the biotech industry.

Congratulations to Associate Professor Too Heng-Phon from the Department of Biochemistry and NUS Centre for Cancer Research at NUS Medicine, who has been conferred the President’s Technology Award 2021.

Across the many functional teams in MiRXES, from R&D to manufacturing and commercial, our women in science wear many different hats — to great success.

Media Contact

For media enquiries, please email:
Copyright © 2024 MiRXES Pte Ltd. All rights reserved. | Privacy Policy
Scroll to Top